{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"12.200","floor":"11.100"},"ipodate":{"start":"2021-01-26 00:00:00","end":"2021-01-29 00:00:00"},"minimumcapital":"12322.94","subscribed":"769.00","marketcap":"288.67億","H_marketcap":"--","pe":"--","codesrate":"7.50","link":"https://staticpdf.iqdii.com/stockdata/notice/02160/2021/2021012600016_c.pdf","ipopricing":"12.200","resultdate":"2021-02-03 00:00:00","enddate":"2021-01-29 00:00:00","listeddate":"2021-02-04 00:00:00","issuenumber":"20562.00萬","issuenumberhK":"10281.00萬","issuenumberother":"10281.00萬","grayprice":"20.20","sponsors":"摩根大通證券(遠東)有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司","raisemoney":"235600.00萬","use":"1、30.0%（或約706.8百萬港元）將被分配予我們的核心產品（即VitaFlowTMII）；\n2、3.4%（或約80.1百萬港元）將被分配予我們首款商業化TAVI產品（即VitaFlowTM）；\n3、27.0%（或約636.1百萬港元）將被分配予我們目前產品管線的其他產品；\n4、15.0%（或約353.4百萬港元）將獲分配用于為通過并購、授權引進或股權投資等方式與包括醫療器械企業及研究機構在內的全球賦能者合作擴展我們的產品組合提供資金；\n5、14.6%（或約344.0百萬港元）將用于擴大我們的產能并提高我們生產VitaFlowTM及VitaFlowTMII的能力；\n6、10.0%（或約235.6百萬港元）將用作我們的營運資金及一般公司用途。","shares":1000,"leadagent":"摩根大通證券(亞太)有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司","bookrunners":"摩根大通證券(亞太)有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司","coordinator":"摩根大通證券(亞太)有限公司,花旗環球金融亞洲有限公司,中國國際金融香港證券有限公司","firstDayOpen":"21.50","IsEiio":0,"Interestdays":5,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"摩根大通證券(亞太)有限公司","code":"E02160","name":"心通醫療－Ｂ","fullname":"微創心通醫療科技有限公司"},"institutioninfo":{"principaloffice":"中國上海市浦東新區張江高科技園區張東路1601號","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"羅七一","secretary":"李香梅,陳濼而","telephone":"(8621) 38954600","substantialshareholders":"Shanghai MicroPort(45.59%),上海鏵浩(8.1%),中金康瑞(7.67%),Qianyi Investment(6.34%)","principalactivities":"公司是一家中國醫療器械企業，專注于心臟瓣膜疾病領域創新的經導管及手術解 決方案的研發和商業化。","website":"https://www.cardioflowmedtech.com"},"managerinfo":[{"managername":"羅七一","post":"董事會主席兼非執行董事","rankno":1},{"managername":"陳國明","post":"總裁兼執行董事","rankno":2},{"managername":"閆璐穎","post":"副總裁兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"CPE Greater China Enterprises Growth Fund","shareholding":"12,710,000.0","percentage":6.2,"ReleaseDate":"2021-08-04 00:00:00","relatedparty":"源峰基金管理有限公司","subsidiary":["CPE Greater China Enterprises Growth Fund","CPE Fund"],"InverstorType":"基金"},{"institutionname":"Hillhouse Funds","shareholding":"9,533,000.0","percentage":4.6,"ReleaseDate":"2021-08-04 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"Lake Bleu Prime Healthcare Master Fund Limited","shareholding":"6,355,000.0","percentage":3.1,"ReleaseDate":"2021-08-04 00:00:00","relatedparty":"清池資本(香港)有限公司","subsidiary":["Lake Bleu Prime Healthcare Master Fund Limited"],"InverstorType":"基金"},{"institutionname":"GIC Private Limited","shareholding":"6,355,000.0","percentage":3.1,"ReleaseDate":"2021-08-04 00:00:00","relatedparty":"","subsidiary":[],"InverstorType":"公司"}],"TotalShareholdingPercentage":38.2},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":9}